AZ’ Lynparza cuts risk of breast cancer progression
AstraZeneca has unveiled new data showing a significant reduction in the risk of death or disease progression in certain patients with breast cancer taking its PARP inhibitor Lynparza.
Read More
Tag: BRCA2
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
